Back to top
more

Avidity Biosciences (RNA)

(Real Time Quote from BATS)

$23.84 USD

23.84
130,192

+0.01 (0.04%)

Updated Apr 26, 2024 11:06 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -46.30% and 93.17%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Akoya (AKYA): Can Its 7.4% Jump Turn into More Strength?

by Zacks Equity Research

Akoya (AKYA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Avidity Biosciences, Inc. (RNA): Can Its 15.0% Jump Turn into More Strength?

by Zacks Equity Research

Avidity Biosciences, Inc. (RNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Bristol Myers (BMY) Partners With SystImmune for Oncology Drug

by Zacks Equity Research

Bristol Myers (BMY) is set to co-develop and co-commercialize oncology candidate BL-B01D1 in the United States with SystImmune.

Will Bristol Myers' (BMY) Efforts to Boost Portfolio be Enough?

by Zacks Equity Research

Shares of Bristol Myers (BMY) have been impacted by pipeline bottlenecks and its key drugs face generic competition. We take a look at the company's efforts to counter these.

The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie

by Zacks Equity Research

Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie are included in this Analyst Blog.

Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More

by Zacks Equity Research

Regulatory and pipeline updates from Avidity Biosciences, Inc. (RNA) and BioVie (BIVI) are in the spotlight this week.

Company News for Nov 29, 2023

by Zacks Equity Research

Companies in The News Are: ESLT,RNA,ZS,SDRL

Avidity (RNA) Expands Collaboration With BMY, Shares Rise

by Zacks Equity Research

Avidity (RNA) gains on the expansion of its existing partnership with BMY to discover multiple cardiovascular targets.

Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 21.43% and 11.08%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 17.78% and 7.15%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Ikena Oncology, Inc. (IKNA) Stock Jumps 7.9%: Will It Continue to Soar?

by Zacks Equity Research

Ikena Oncology, Inc. (IKNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

The Zacks Analyst Blog Highlights bluebird, Oncternal Therapeutics, Avidity, Ascendis and Vertex Pharmaceuticals

by Zacks Equity Research

bluebird, Oncternal Therapeutics, Avidity, Ascendis and Vertex Pharmaceuticals are included in this Analyst Blog.

Biotech Stock Roundup: BLUE Announces Q4 Results, ONCT, ASND & RNA Fall on Updates

by Zacks Equity Research

Earnings and pipeline updates from bluebird bio (BLUE) and Avidity (RNA) are the key highlights for the biotech sector.

Avidity (RNA) Down on Update From Neuromuscular Disease Study

by Zacks Equity Research

Avidity Biosciences (RNA) provides an update on its phase I/II study of its lead product candidate AOC 1001 for the treatment of myotonic dystrophy type I. The stock falls about 17%.

Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -4.76% and 15.86%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Down 15.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Avidity Biosciences, Inc. (RNA)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Avidity Biosciences, Inc. (RNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 15.46% and 3.85%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Clene Inc. (CLNN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Clene Inc. (CLNN) delivered earnings and revenue surprises of 39.13% and 228.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Vir Biotechnology, Inc. (VIR) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 12,900% and 143.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Avidity (RNA) Down on Partial Hold of Myotonic Dystrophy Study

by Zacks Equity Research

Avidity Biosciences (RNA) reports FDA-imposed partial hold on enrolling new patients in its phase I/II MARINA study evaluating AOC 1001 in myotonic dystrophy type 1 in adults. Stock down.

Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -24.32% and 4.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Avidity Biosciences, Inc. (RNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Avidity Biosciences, Inc. (RNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What Makes Avidity Biosciences, Inc. (RNA) a New Buy Stock

by Zacks Equity Research

Avidity Biosciences, Inc. (RNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts Believe Avidity Biosciences, Inc. (RNA) Could Rally 242%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Avidity Biosciences, Inc. (RNA) points to a 241.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.